NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Gelteq Ltd. GELS
3 fiscal years on record · AUD · FY2024 reported · SEC filings only
In brief
What this company does
Written from the business description in Gelteq Limited's annual report to the U.S. Securities and Exchange Commission, filed 17 November 2025. Every sentence was checked against that document before publication.
Growth
AUD 165,645.00
Revenue, FY2024 · full 3-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2024 · Operating -3317.7%
ROE
Not available in our data for this period.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · AUD
row low → row highnegative
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue AUD B | 0.0 | · | 0.0 |
| Operating income AUD B | −0.0 | −0.0 | −0.0 |
| EBITDA AUD B | −0.0 | −0.0 | −0.0 |
| Income tax AUD B | · | · | · |
| Net income $B | −0.0 | −0.0 | · |
| Free cash flow AUD B | −0.0 | −0.0 | −0.0 |
| EPS, diluted AUD | −0.72 | −0.44 | −0.44 |
| Dividend / sh AUD | · | · | · |
| Payout % | · | · | · |
| ROE % | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 13 reconciliationsAUDITED
Reconciled in 1 of 19 fiscal years. 82 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2022